Abstract
Objective: to study the efficacy of metaprot in the treatment of neurasthenia. Patients and methods. Thirty patients aged 18 to 45 years with neurasthenia (F48.0) were followed up. The patients were examined using a subjective asthenia rating scale (Multidimensional Fatigue Inventory (MFI-20)), a 10-point anesthesia visual analog scale, Spielberger’s self-report scale modified by Yu.L. Khanin, and a computed Test of Variables of Attention (TOVA). Metaprot was given in a dose of 0.25 g b.i.d. after morning and evening meals as two administrations for 10 days (5 days at a 2-day interval). The results of therapy were assessed on day 30 after its course. Results. There was clinical improvement in 21 (70.0%) patients after metaprot therapy. Evaluation of the patient’s status using the MFI-20 showed a significant improvement in the items of general asthenia, physical asthenia, psychic asthenia, and decreased activity. Psychophysiological examination using the TOVA revealed a significant reduction in response times, as compared to the scores obtained before the treatment, and a decrease in the number of errors in the second half of the test, which allows us to state that there is a reduction in the degree of mental exhaustion and an increase in work capacity after the treatment. Psychological tests showed no significant reduction in anxiety scores. There were no adverse reactions or complications. It has been concluded that it is promising to use metaprot to treat neurasthenia.
Highlights
Objective: to study the efficacy of metaprot in the treatment of neurasthenia
Metaprot was given in a dose of 0.25 g b.i.d. after morning and evening meals as two administrations for 10 days (5 days at a 2-day interval)
Psychophysiological examination using the Test of Variables of Attention (TOVA) revealed a significant reduction in response times, as compared to the scores obtained before the treatment, and a decrease in the number of errors in the second half of the test, which allows us to state that there is a reduction in the degree of mental exhaustion and an increase in work capacity after the treatment
Summary
Цель исследования – изучение эффективности препарата метапрот при лечении неврастении. В число соматических и психических нарушений, характерных для неврастении, он включил 44 симптома, в происхождении которых общим является умственное перенапряжение, вызывающее «нервное истощение» Strü mpel писал: «Эта болезнь столь же стара, как и вообще многие наши сведения о болезнях человека; и если многие склонны видеть причину увеличения частоты неврастении в беспрерывной сутолоке, в беспокойстве и возбуждениях современной жизни, то стоит только вглядеться в историю предыдущих веков с их ужасами и бесконечными войнами, чтобы убедиться, что взгляд этот крайне ошибочен. В результате снижения обращаемости таких пациентов к психиатрам, во-вторых, с введением классификации МКБ-10 диагноз неврастении стал чаще подменяться другими диагностическими категориями, такими как «соматоформное расстройство», «расстройство адаптации» и др. Динамикаклинико - психологическихпоказателей ноз ставили на основании критериев у пациентов с неврастенией до и после лечения
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
